The protein-cleaving enzyme caspase-2 appears to be a key driver of non-alcoholic steatohepatitis, researchers in California have found.
The findings demonstrate that blocking the enzyme could halt the progression of liver damage that leads to NASH, and could possibly even reverse early symptoms of the disease, according to the researchers (Cell 2018 Sep 13. [Epub ahead of print]).
“Our results show that caspase-2 is a critical mediator of NASH pathogenesis, not only in mice but probably in